Pretti M, Vieira G, Boroni M, Bonamino M
Brief Bioinform. 2025; 26(1).
PMID: 39831892
PMC: 11744606.
DOI: 10.1093/bib/bbaf012.
Karuppiah V, Sangani D, Whaley L, Pengelly R, Uluocak P, Carreira R
Sci Rep. 2024; 14(1):26851.
PMID: 39500929
PMC: 11538495.
DOI: 10.1038/s41598-024-75140-7.
Dolton G, Bulek A, Wall A, Thomas H, Hopkins J, Rius C
J Clin Invest. 2024; 134(18).
PMID: 39286976
PMC: 11405051.
DOI: 10.1172/JCI164535.
Caragea A, Ursu R, Maruntelu I, Tizu M, Constantinescu A, Talangescu A
Int J Mol Sci. 2024; 25(16).
PMID: 39201523
PMC: 11354460.
DOI: 10.3390/ijms25168837.
Wang A, Lin X, Chau K, Onuchic J, Levine H, George J
Sci Adv. 2024; 10(20):eadl0161.
PMID: 38748791
PMC: 11095454.
DOI: 10.1126/sciadv.adl0161.
Systematic immune cell dysregulation and molecular subtypes revealed by single-cell RNA-seq of subjects with type 1 diabetes.
Honardoost M, Adinatha A, Schmidt F, Ranjan B, Ghaeidamini M, Rayan N
Genome Med. 2024; 16(1):45.
PMID: 38539228
PMC: 10976681.
DOI: 10.1186/s13073-024-01300-z.
Comprehensive epitope mutational scan database enables accurate T cell receptor cross-reactivity prediction.
Banerjee A, Pattinson D, Wincek C, Bunk P, Axhemi A, Chapin S
bioRxiv. 2024; .
PMID: 38370810
PMC: 10871174.
DOI: 10.1101/2024.01.22.576714.
Non-mutational neoantigens in disease.
Stern L, Clement C, Galluzzi L, Santambrogio L
Nat Immunol. 2024; 25(1):29-40.
PMID: 38168954
PMC: 11075006.
DOI: 10.1038/s41590-023-01664-1.
Monitoring immunomodulation strategies in type 1 diabetes.
Krishnamurthy B, Lacorcia M, Kay T, Thomas H, Mannering S
Front Immunol. 2023; 14:1206874.
PMID: 37346035
PMC: 10279879.
DOI: 10.3389/fimmu.2023.1206874.
Immune engineered extracellular vesicles to modulate T cell activation in the context of type 1 diabetes.
Becker M, Peters L, Myint T, Smurlick D, Powell A, Brusko T
Sci Adv. 2023; 9(22):eadg1082.
PMID: 37267353
PMC: 10765990.
DOI: 10.1126/sciadv.adg1082.
The need and benefit of immune monitoring to define patient and disease heterogeneity, mechanisms of therapeutic action and efficacy of intervention therapy for precision medicine in type 1 diabetes.
Roep B
Front Immunol. 2023; 14:1112858.
PMID: 36733487
PMC: 9887285.
DOI: 10.3389/fimmu.2023.1112858.
Structural plasticity in I-A links autoreactivity to hybrid insulin peptides in type I diabetes.
Erausquin E, Serra P, Parras D, Santamaria P, Lopez-Sagaseta J
Front Immunol. 2022; 13:924311.
PMID: 35967292
PMC: 9365947.
DOI: 10.3389/fimmu.2022.924311.
Rhomboid protease RHBDL4 promotes retrotranslocation of aggregation-prone proteins for degradation.
Bock J, Kuhnle N, Knopf J, Landscheidt N, Lee J, Ye Y
Cell Rep. 2022; 40(6):111175.
PMID: 35947953
PMC: 9437926.
DOI: 10.1016/j.celrep.2022.111175.
Identification of Key Genes and Pathways in Peripheral Blood Mononuclear Cells of Type 1 Diabetes Mellitus by Integrated Bioinformatics Analysis.
Li X, Liao M, Guan J, Zhou L, Shen R, Long M
Diabetes Metab J. 2022; 46(3):451-463.
PMID: 35381625
PMC: 9171163.
DOI: 10.4093/dmj.2021.0018.
Integrative immunoinformatics paradigm for predicting potential B-cell and T-cell epitopes as viable candidates for subunit vaccine design against COVID-19 virulence.
Sarma V, Olotu F, Soliman M
Biomed J. 2021; 44(4):447-460.
PMID: 34489196
PMC: 8130595.
DOI: 10.1016/j.bj.2021.05.001.
Droplet-based mRNA sequencing of fixed and permeabilized cells by CLInt-seq allows for antigen-specific TCR cloning.
Nesterenko P, McLaughlin J, Cheng D, Bangayan N, Burton Sojo G, Seet C
Proc Natl Acad Sci U S A. 2021; 118(3).
PMID: 33431692
PMC: 7826406.
DOI: 10.1073/pnas.2021190118.
Optimization of a Method to Detect Autoantigen-Specific T-Cell Responses in Type 1 Diabetes.
Musthaffa Y, Nel H, Ramnoruth N, Patel S, Hamilton-Williams E, Harris M
Front Immunol. 2021; 11:587469.
PMID: 33424839
PMC: 7793893.
DOI: 10.3389/fimmu.2020.587469.
TCR Recognition of Peptide-MHC-I: Rule Makers and Breakers.
Szeto C, Lobos C, Nguyen A, Gras S
Int J Mol Sci. 2020; 22(1).
PMID: 33374673
PMC: 7793522.
DOI: 10.3390/ijms22010068.
Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?).
Roep B, Thomaidou S, van Tienhoven R, Zaldumbide A
Nat Rev Endocrinol. 2020; 17(3):150-161.
PMID: 33293704
PMC: 7722981.
DOI: 10.1038/s41574-020-00443-4.
Insulin-Reactive T Cells Convert Diabetogenic Insulin-Reactive VH125 B Cells Into Tolerogenic Cells by Reducing Germinal Center T:B Cell Interactions in NOD Mice.
Pearson J, Li Y, Majewska-Szczepanik M, Guo J, Zhang L, Liu Y
Front Immunol. 2020; 11:585886.
PMID: 33262765
PMC: 7688534.
DOI: 10.3389/fimmu.2020.585886.